

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|---|----|---|--------------------------|------------------------|
| Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | | | Complete if Known | |
| | | | | Application Number | 10/565,885 |
| | | | | Filing Date | January 25, 2006 |
| | | | | First Named Inventor | LOPEZ DE SILANES, Juan |
| | | | | Art Unit | 1618 |
| | | | | Examiner Name | To Be Assigned |
| Sheet | 1 | of | 4 | Attorney Docket Number | 2399.0080000/JAG/LAV |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|--|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published | T ² |
| | NPL1 | BECERRIL, B., <i>et al.</i> , "Cloning and characterization of cDNAs that code for Na ⁺ - channel-blocking toxins of the scorpion <i>Centruroides noxius</i> Hoffman," <i>Gene</i> 128:165-171, Elsevier Science Publishers B.V. (1993) | |
| | NPL2 | CAIN, B.S., <i>et al.</i> , "The Physiologic Basis for Anticytokine Clinical Trials in the Treatment of Sepsis," <i>J. Am. Coll. Surg.</i> 186:337-351, American College of Surgeons (1998) | |
| | NPL3 | CALDERON-ARANDA, E.S., <i>et al.</i> , "Neutralizing Capacity of Murine Sera Induced by Different Antigens of Scorpion Venom," <i>Toxicon</i> 31:327-337, Pergamon Press Ltd. (1993) | |
| | NPL4 | CALDERON-ARANDA, E.S., <i>et al.</i> , "The use of synthetic peptides can be a misleading approach to generate vaccines against scorpion toxins," <i>Vaccine</i> 13:1198-1206, Elsevier Science, Ltd. (1995) | |
| | NPL5 | COURAUD, F., <i>et al.</i> , "Two Types of Scorpion Toxin Receptor Sites, One Related to the Activation, the Other to the Inactivation of the Action Potential Sodium Channel," <i>Toxicon</i> 20:9-16, Pergamon Press Ltd. (1982) | |
| | NPL6 | DEHESA-DÁVILA, M. and Possani, L.D., "Scorpionism and Serotherapy in Mexico," <i>Toxicon</i> 32:1015-1018, Elsevier Science Ltd. (1994) | |
| | NPL7 | DEHESA-DÁVILA, M., <i>et al.</i> , "Clinical Toxicology of Scorpion Stings," in <i>Handbook of Clinical Toxicology of Animal Venoms and Poisons</i> , Ch. 18, Meier, J., and White, J., eds., CRC Press, Boca Raton, FL, pp. 221-238 (1995) | |
| | NPL8 | Abstract of DICK, A.D., <i>et al.</i> , "Neutralizing TNF-alpha Activity Modulates T-cell Phenotype and Function in Experimental Autoimmune Uveoretinitis," <i>J. Autoimmun.</i> 11:255-264 (1998) | |
| | NPL9 | EDMAN, P. and Begg, G., "A Protein Sequenator," <i>Eur. J. Biochem.</i> 1:80-91, Blackwell Science, Ltd. on behalf of the Federation of European Biochemical Societies (1967) | |
| | NPL10 | FEKADE, D., <i>et al.</i> , "Prevention of Jarisch-Herxheimer Reactions by Treatment with Antibodies Against Tumor Necrosis Factor α ," <i>N. Engl. J. Med.</i> 335:311-315, Massachusetts Medical Society (1996) | |

| | |
|--------------------|-----------------|
| Examiner Signature | Date Considered |
|--------------------|-----------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

ALL REFERENCES CONSIDERED EXPERT WHERE LINED THROUGH. /Z.S./

Equivalent of Form PTO/SB/08B (09-06)

Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|---|----|---|--------------------------|------------------------|
| Substitute for form 1449/PTO | | | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | | | Application Number | 10/565,885 |
| | | | | Filing Date | January 25, 2006 |
| | | | | First Named Inventor | LOPEZ DE SILANES, Juan |
| | | | | Art Unit | 1618 |
| | | | | Examiner Name | To Be Assigned |
| Sheet | 2 | of | 4 | Attorney Docket Number | 2399.0080000/JAG/LAV |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|---|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published | T ² |
| | NPL11 | FOX, D.A., "Cytokine Blockade as a New Strategy to Treat Rheumatoid Arthritis," <i>Arch. Intern. Med.</i> 160:437-444, American Medical Association (2000) | |
| | NPL12 | GARCÍA, C., <i>et al.</i> , "Isolation, Characterization and Comparison of Novel Crustacean Toxin with a Mammalian Toxin from the Venom of the Scorpion <i>Centruroides noxius</i> Hoffman," <i>Comp. Biochem. Physiol.</i> 116B:315-322, Elsevier Science, Inc. (1997) | |
| | NPL13 | KRUEGER, J.G., "The immunologic basis for the treatment of psoriasis with new biologic agents," <i>J. Am. Acad. Dermatol.</i> 46:1-23, American Academy of Dermatology, Inc. (January 2002) | |
| | NPL14 | LEGROS, C., <i>et al.</i> , "Use of fusion protein constructs to generate potent immunotherapy and protection against scorpion toxins," <i>Vaccine</i> 20:934-942, Elsevier Science, Ltd. (2002) | |
| | NPL15 | LICEA, A.F., <i>et al.</i> , "FAB Fragments of the Monoclonal Antibody BCF2 are Capable of Neutralizing the Whole Venom from the Scorpion <i>Centruroides noxius</i> Hoffman," <i>Toxicon</i> 34:843-847, Elsevier Science Ltd. (1996) | |
| | NPL16 | LISMAN, K.A., <i>et al.</i> , "Managing Heart Failure with Immunomodulatory Agents," <i>Cardiol. Clin.</i> 19:617-625, W.B. Saunders Co. (2001) | |
| | NPL17 | LUGER, T., "Treatment of immune-mediated skin diseases: future perspectives," <i>Eur. J. Dermatol.</i> 11:343-347, accessed at http://www.john-libbey-eurotext.fr/en/revues/medecine/ejd/e-docs/00/01/88/A6/article.md , John Libbey Eurotext (2001) | |
| | NPL18 | MARABOTO MARTINEZ, J.A., <i>et al.</i> , "Panorama Epidemiológico de las Intoxicaciones Causadas por Animales Ponzosos en la Población Derechohabiente del IMSS 1990-1998," in 3 ^a <i>Reunión de Expertos en Envenenamiento por Animales Ponzosos</i> , Instituto de Biotecnología, Universidad Nacional Autónoma de México, Alcapulco, Gro., México (February 17-19, 1999) | |
| | NPL19 | English translation of Maraboto Martinez, J.A., <i>et al.</i> , "Panorama Epidemiológico de las Intoxicaciones Causadas por Animales Ponzosos en la Población Derechohabiente del IMSS 1990-1998," in 3 ^a <i>Reunión de Expertos en Envenenamiento por Animales Ponzosos</i> , Instituto de Biotecnología, Universidad Nacional Autónoma de México, Alcapulco, Gro., México (February 17-19, 1999) | |
| | NPL20 | MARTIN, G.S., "Current Management Strategies for Severe Sepsis and Septic Shock," Presented at Chest 2001: 67th Annual Scientific Assembly of the American College of Chest Physicians, November 4-8, 2001, Philadelphia, PA, accessed online at http://www.medscape.com/viewarticle/412927 , Medscape Portals, Inc., 4 pages (2001) | |

| | |
|--------------------|-----------------|
| Examiner Signature | Date Considered |
|--------------------|-----------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

ALL REFERENCES COMPLETED EXCEPT WHERE LINED THROUGH. /Z.S./

Equivalent of Form PTO/SB/08B (09-06)

Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|---|----|---|--------------------------|------------------------|
| Substitute for form 1449/PTO | | | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | | | Application Number | 10/565,885 |
| | | | | Filing Date | January 25, 2006 |
| | | | | First Named Inventor | LOPEZ DE SILANES, Juan |
| | | | | Art Unit | 1618 |
| | | | | Examiner Name | To Be Assigned |
| Sheet | 3 | of | 4 | Attorney Docket Number | 2399.0080000/JAG/LAV |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|---|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published | T ² |
| | NPL21 | NONNER, W., "Effects of <i>Leiurus</i> Scorpion Venom on the "Gating" Current in Myelinated Nerve," <i>Adv. Cytopharmacol.</i> 3:345-352, Raven Press (1979) | |
| | NPL22 | POSSANI, L.D., <i>et al.</i> , "Scorpion toxins from <i>Centruroides noxius</i> and <i>Tityus serrulatus</i> ," <i>Biochem. J.</i> 229:739-750, Biochemical Society/Portland Press (1985) | |
| | NPL23 | POSSANI, L.D., <i>et al.</i> , "Scorpion toxins specific for NA ⁺ -channels," <i>Eur. J. Biochem.</i> 264:287-300, Blackwell Science, Ltd. on behalf of the Federation of European Biochemical Societies (1999) | |
| | NPL24 | POSSANI, L.D., <i>et al.</i> , "Peptides and genes coding for scorpion toxins that affect ion-channels," <i>Biochimie</i> 82:861-868, Editions Scientifiques Elsevier (2000) | |
| | NPL25 | PRESENT, D.H., <i>et al.</i> , "Infliximab for the Treatment of Fistulas in Patients with Crohn's Disease," <i>N. Engl. J. Med.</i> 340:1398-1405, Massachusetts Medical Society (1999) | |
| | NPL26 | QIAN, Y., <i>et al.</i> , "Topical Soluble Tumor Necrosis Factor Receptor Type I Suppresses Ocular Chemokine Gene Expression and Rejection of Allogenic Corneal Transplants," <i>Arch. Ophthalmol.</i> 118:1666-1671, American Medical Association (2000) | |
| | NPL27 | STAPCZYNSKI, J.S., "Shock, Septic," Dire, D.J., <i>et al.</i> , eds., eMedicine.com Inc., accessed online at http://emedicine.com/EMERG/topic533.htm , eMedicine.com, Inc., 25 pages (2004) | |
| | NPL28 | STRICHARTZ, G., <i>et al.</i> , "An Integrated View of the Molecular Toxinology of Sodium Channel Gating in Excitable Cells," <i>Ann. Rev. Neurosci.</i> 10:237-267, Annual Reviews, Inc. (1987) | |
| | NPL29 | TORRES, P.F., and KIJLSTRA, A., "The role of cytokines in corneal immunopathology," <i>Ocul. Immunol. Inflamm.</i> 9:9-24, Swets & Zeitlinger (2001) | |
| | NPL30 | ZAMUDIO, F., <i>et al.</i> , "Amino acid sequence and immunological characterization with monoclonal antibodies of two toxins from the venom of the scorpion <i>Centruroides noxius</i> Hoffman," <i>Eur. J. Biochem.</i> 204:281-292, Blackwell Science, Ltd. on behalf of the Federation of European Biochemical Societies (1992) | |

| | |
|--------------------|-----------------|
| Examiner Signature | Date Considered |
|--------------------|-----------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

ALL REFERENCES CONSIDERED EXPERT WHERE LINED THROUGH. /Z.S./

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|--|----------------|----|---|--------------------------|------------------------|
| Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | | | Complete if Known | |
| | | | | Application Number | 10/565,885 |
| | | | | Filing Date | January 25, 2006 |
| | | | | First Named Inventor | LOPEZ DE SILANES, Juan |
| | | | | Art Unit | 1618 |
| Examiner Name | To Be Assigned | | | | |
| Sheet | 4 | of | 4 | Attorney Docket Number | 2399.0080000/JAG/LAV |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|--|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issuc number(s), publisher, city and/or country where published | T ² |
| | NPL31 | ZHU, S., <i>et al.</i> , "Early Expression of Proinflammatory Cytokines Interleukin-1 and Tumor Necrosis Factor- α after Corneal Transplantation," <i>J. Interferon. Cytokine. Res.</i> 19:661-669, Mary Ann Liebert, Inc. (1999) | |
| | NPL32 | International Search Report for International Patent Application No. PCT/MX02/00013, European Patent Office, Netherlands, mailed on August 16, 2002 | |
| | NPL33 | Dialog File 351, Accession No. 9271133, Derwent WPI English language abstract for Spanish Patent No. 2 106 183 (Document FP1) | |
| | NPL34 | English language translation of Secretaría de Salud, "Pyrogen Tests," in: <i>Farmacopea de los Estados Unidos Mexicanos</i> , Vol. I, Secretaría de Salud, Mexico City, MX, pp. 334-335 (2000) | |
| | NPL35 | English language translation of Secretaría de Salud, "Potency of Anti-Poison Sera," in <i>Farmacopea de los Estados Unidos Mexicanos</i> , Vol. II, Secretaría de Salud, Mexico City, MX, pp. 1756-1757 (2000) | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |

642463_1

| | | | |
|--------------------|--------------------|-----------------|------------|
| Examiner Signature | /Zachary Skelding/ | Date Considered | 08/16/2008 |
|--------------------|--------------------|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /Z.S./